Search results
Results from the WOW.Com Content Network
Dual antiplatelet therapy (DAPT) is recommended for 1 month following bare metal stent placement, for 3 months following a second generation drug-eluting stent placement, and for 6–12 months following a first generation drug-eluting stent placement. [1] DAPT's antiplatelet properties are intended to prevent blood clots, however they also ...
In patients with truly time-sensitive disease (defined in the 2014 ACC/AHA guidelines as needing to proceed in 2–6 weeks), DAPT can be stopped 3 (three) months (90 days) after a coronary stent is placed if postponing surgery any longer would result in significant morbidity.
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option. Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
[1] [2] As a result, dual therapy stents were developed to reduce the long-term need for dual-antiplatelet therapy. [3] The COMBO stent is the first and only dual therapy stent that addresses the challenges of vessel healing in drug-eluting stents. [4] This stent is an anti-CD34 antibody-coated and sirolimus-eluting bioresorbable stent. [2]
“The public should know that aspirin remains an important treatment for a heart attack, and in these studies, it was an essential therapy in the 3 months after receiving the stent,” Dr. Harlan ...
A coronary stent is a tube-shaped device placed in the coronary arteries that supply blood to the heart, to keep the arteries open in patients suffering from coronary heart disease. The vast majority of stents used in modern interventional cardiology are drug-eluting stents (DES).
A drug-eluting stent (DES) is a small mesh tube that is placed in the arteries to keep them open in the treatment of vascular disease.The stent slowly releases a drug to block cell proliferation (a biological process of cell growth and division), thus preventing the arterial narrowing that can occur after stent implantation.
After sharp criticism from anesthesiologists, an insurance company is halting its plan to limit the amount time it would cover anesthesia used in surgeries and procedures.